Study Shows Only About One-Third of People With NSCLC Are Benefiting From Appropriate Care

The FDA has approved around 100 targeted therapies for different types of cancer, with many more in the pipeline. Current agents for non-small cell lung cancer (NSCLC), for example, target about 10 different biomarkers, and more than 70% of people with the condition have alterations in their tumors that are tied to available treatments. But a recent study found that due to practice gaps in the precision oncology pathway, just more than one-third of patients with biomarkers that could be treated with an FDA-approved therapy are actually benefiting from those drugs.

Lung cancer is one of the most common types of cancer, and NSCLC makes up the bulk of the cases. Many of the more than two dozen agents approved for NSCLC are targeted therapies that are indicated for specific subsets of the disease, and numerous tests are available to help providers determine the best treatment for a patient.

© 2024 MMIT
Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

December 16

Biomarker Testing Is Not Keeping Up With Drug Innovations

Read More
March 1

Evolution of Medicine Has Produced Novel New Treatments

Read More
December 8

Collaboration Is Needed Among Stakeholders for Genetic Tests to Be Beneficial



Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today